Black Diamond Q1 net loss $18.2M; cash $115.2M; Phase 2 BDTX-1535 data on track for Q3 2024

Black Diamond Therapeutics, Inc.

2024-Q1 EPS reported -$0.35

Net loss of $18.2M for Q1 2024 vs $20.9M in Q1 2023; R&D exp $13.5M, G&A $6.7M.
Cash, equivalents, investments $115.2M as of Mar 31, 2024; runway into Q3 2025.
Phase 2 BDTX-1535 in 2L/3L EGFRm NSCLC initial data expected Q3 2024; 1L cohort enrollment ongoing, data Q1 2025.
ASCO June 1: Phase 1 BDTX-1535 GBM dose-escalation and window-of-opportunity trial results.
Board changes: Shannon Campbell and Prakash Raman appointed; Wendy Dixon and Alex Mayweg stepped down.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Black Diamond Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income $18.2 million.

Period: the first quarter ended March 31, 2024
Net income: $18.2 million
Result: reported results

Exact text from the filing

Net loss for the first quarter of 2024 was $18.2 million

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Black Diamond Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001701541-24-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.